Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for DYN
Across the 28 sessions after earlier DYN headlines, the stock closed higher 18 times and lower 10 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DYN | SPY |
|---|---|---|---|
| Sep 30, 2026 | Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | -0.6% | -0.2% |
| Sep 18, 2026 | Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -5.3% | -0.1% |
| Sep 9, 2026 | Dyne Therapeutics downgraded by Analyst with a new price target | -5.5% | -0.5% |
| Sep 3, 2026 | Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting | -0.8% | +1.0% |
| Sep 2, 2026 | Dyne Therapeutics to Participate in Upcoming Investor Conferences | +0.2% | +0.4% |
| Aug 21, 2026 | Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +0.5% | +0.4% |
Quantisnow market dataNASDAQ
DYN
Dyne Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for DYN
Full DYN profile on Quantisnow Follow DYN and get a push notification the moment its next story breaks.